[Replay] Videoconference: Company’s Latest News, Outlook, and R&D Activities
May 15, 2024
May 15, 2024
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024
May 8, 2024
[Replay] Videoconference • Collaboration with AbbVie (French)
April 17, 2024
April 17, 2024
Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
April 16, 2024
April 16, 2024
[Replay] Medincell Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 11, 2024
April 11, 2024
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
April 8, 2024
April 8, 2024
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell’s Supervisory Board
March 13, 2024
March 13, 2024
[Replay] Medincell Presentation at Evercore ISI 2024 Emerging Biotech Conference
